Compare GSK plc (GSK) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Invesco S&P 500 Momentum ETF — how do they compare? GSK plc trades at $51.15 (market cap $102.60B), while Invesco S&P 500 Momentum ETF trades at $151.08. The key difference: GSK plc pays a 3.57% dividend while Invesco S&P 500 Momentum ETF pays none, and Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | SPMO | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $161.66 |
52-Week Low | $38.22 | $107.84 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
SPMO, trading at $151.89 with a 2.15% daily gain, shows strong momentum-driven performance, supported by a bullish technical signal from moving averages and positive media coverage highlighting its 26% returns year-to-date. The ETF's concentrated, tech-heavy portfolio leverages AI growth trends, though key financial ratios like P/E and P/S are not disclosed in the provided data. A dividend of $0.25 is scheduled for June 2026, adding income potential for investors.
The outlook for SPMO remains favorable due to sustained momentum factor strength and institutional interest, but risks include high volatility from sector concentration and potential downturns during market rotations. Investors should weigh the ETF's cost efficiency and historical outperformance against its exposure to tech sector swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
